A ntisense (LICA) medicines. The agreement provides Ionis exclusive access to Bicycle's proprietary macrocyclic peptides, referred to as Bicycles , to design LICAs that target transferrin receptor 1 for use with oligonucleotides. This LICA strategy has …

2022年11月10日 · 递送技术上，Ionis的配体共轭反义（LICA，ligand conjugated antisense）技术平台，能够将更大剂量的ASO递送到所需细胞和组织，并实现了不但让ASO药物可以通过多种方法给药，而且可以送达到人体的不同器官和组织中。

2021年7月14日 · 今日，Ionis Pharmaceuticals和Bicycle Therapeutics联合宣布，双方达成合作协议，将利用Bicycle公司独有的双环肽技术，扩展Ionis的配体偶联反义（LICA）药物的 ...

此外，Ionis也有自己的核心递送技术LICA（Ligand Conjugated Antisense），LICA可将一个Ligand与核酸药物相连接，使ASO可以通过该Ligand与特定的细胞受体结合，实现靶向递送。

2024年7月1日 · Discovered and developed by Ionis, donidalorsen is an investigational RNA-targeted LIgand-Conjugated Antisense (LICA) medicine designed to designed to target prekallikrein (PKK), which plays an important role in activating inflammatory mediators associated with acute attacks of hereditary angioedema (HAE). By reducing the production

After internalization into cells by the ASGR1‐mediated endocytic pathway, the GalNAc 3 cluster is metabolized to release ‘free ASO’ inside the hepatocyte for binding to the target mRNA. 18 The ligand‐conjugated antisense (LICA) technology has provided a 20‐fold to 30‐fold increase in potency for targets expressed by liver ...

2021年7月13日 · The agreement with Bicycle Therapeutics represents a strategic addition to our expanding LICA platform, giving us the potential to meaningfully expand our drug discovery capabilities and deliver...

2025年3月11日 · Ionis Owned Donidalorsen, formerly known as IONIS-PKK-L Rx , is an investigational RNA-targeted medicine designed to target the production of prekallikrein (PKK), which plays an important role in the activation of inflammatory mediators associated with acute attacks of hereditary angioedema (HAE).

2022年7月13日 · IONIS-FB-L Rx 是一种使用Ionis 的 LIgand Conjugated Antisense (LICA) 技术设计的反义药物，旨在减少补体先天免疫系统中的关键蛋白补体因子B（FB）的产生。FB主要在肝脏中产生并在整个血管系统中循环，包括眼睛和肾脏中的血管。

ionis配体偶联反义（lica）技术是一种创新的药物研发方法，旨在提高反义寡核苷酸（aso）的靶向性和疗效。 LICA技术的核心原理在于将特定的配体（如GalNAc）与反义寡核苷酸（ASO）偶联，从而实现针对特定组织和细胞的精准递送。